Organogenesis Holdings Inc. (ORGO) stock analysis
Close on Nov 12, 2026Market cap $124.17MP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak8 of 30 checks passed
Organogenesis passes 8 of the 30 checks behind our score; 11 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 1/6
- Growth
- 0/6
- Past performance
- 2/6
- Financial health
- 5/6
- Dividend
- 0/6
What stands out
No debt
Organogenesis has no borrowings on its latest balance sheet.
Earnings grew over 5 years
Net income grew 16.5% a year on average over the last five fiscal years.
Interest well covered
No meaningful interest expense to cover.
Debt covered by cash flow
There is no debt to cover.
What to watch
Return on equity under 15%
Return on equity was -72.2% over the last twelve months and averaged 14.1% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -47.0%, below the 10% that usually covers the cost of capital.
Revenue growing under 10% a year
Revenue grew 7.8% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew 7.7% a year over the last three fiscal years.
Valuation1/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B below the industry
Organogenesis's price-to-book of 1.13 is below the Drugs median of 2.29.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth0/6
Revenue growing under 10% a year
Revenue grew 7.8% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew 7.7% a year over the last three fiscal years.
Earnings growth not accelerating
Net income grew -13568% over the last twelve months, against a 5-year average of 16.5% a year.
Growing slower than the industry
Revenue grew -24.3% over the last twelve months; the Drugs median is 8.0%.
Guidance lowered
Organogenesis lowered its year ending December 31, 2026 Total net revenue outlook on Aug 6, 2026.
Gross margin trend
This company does not report gross profit.
Past performance2/6
Return on equity under 15%
Return on equity was -72.2% over the last twelve months and averaged 14.1% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -47.0%, below the 10% that usually covers the cost of capital.
Return on equity below the industry
Organogenesis's return on equity of -72.2% is below the Drugs median of -58.9%.
Earnings grew over 5 years
Net income grew 16.5% a year on average over the last five fiscal years.
Net margin below its 5-year average
Net margin was -38.4% over the last twelve months, against a 5-year average of 6.3%.
Net margin above the industry
Organogenesis's net margin of -38.4% is above the Drugs median of -53.0%.
Financial health5/6
No debt
Organogenesis has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 3.32 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is 0.61; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Organogenesis has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Organogenesis. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 20.1
- Drugs median 25.1
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
High risk
- Average value traded per day
- $1.05M
- Value traded per 1% price move
- $263.68K
Downside
High risk
- Typical loss in a bad month
- 39.8%
- Volatility (annualized)
- 66%
- Sharpe ratio, 1 year
- -1.35
- Beta to the S&P 500 (5Y)
- 1.18
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +17.0% | +7.8% | +10.8% | – | |
| Operating income | – | +26.1% | +10.9% | – | |
| Net income | +4201.0% | +33.6% | +16.5% | – | |
| EPS, diluted | – | +7.7% | 0.0% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 272.6% | 17.8% | 13.2% | |
| Return on assets | -10.9% | 6.7% | 6.8% | |
| Current ratio | 3.00 | 2.56 | 3.62 | |
| Debt to equity | – | – | – | |
| Interest coverage | -1.6× | 2.4× | -19.6× | |
| Inventory turnover | – | 3.4× | – | |
| Capex to revenue | 1.0% | 5.2% | 2.5% | |
| Diluted shares | 63M | 111M | 130M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Organogenesis generated $142.27M from operations and spent $139.14M on capital expenditure, dividends and share buybacks. 82% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 6.6% | 1.03× | 1.95× | 13.2% |
| FY2024 | 0.2% | 1.01× | 1.77× | 0.3% |
| FY2023 | 1.1% | 0.95× | 1.67× | 1.8% |
| FY2022 | 3.4% | 1.01× | 1.76× | 6.1% |
| FY2021 | 20.2% | 1.27× | 1.91× | 49.2% |
| FY2020 | 5.1% | 1.32× | 2.64× | 17.8% |
| FY2019 | -14.8% | 1.36× | 4.18× | -84.2% |
| FY2018 | -33.5% | 1.24× | 12.69× | -526.6% |
| FY2017 | -4.2% | 0.86× | -14.70× | 53.6% |
| FY2016 | -12.2% | 0.89× | -25.02× | 272.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$37.03M
- Cash generatingOperating cash flow above zero-$10.31M
- Return on assets improvedROA up on the prior year0.2% → 7.4%
- Earnings backed by cashOperating cash flow above net income-$10.31M vs $37.03M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.69 → 3.62
- No dilutionShare count did not rise132M → 130M
- Gross margin improvedGross margin up on the prior year75.99% → –
- More efficientAsset turnover rose1.05 → 1.13
See a number that looks wrong?